Meeting
2023 ASCO Quality Care Symposium
Real-world (RW) use of niraparib (Nir) monotherapy (mono) as first-line (1L) switch maintenance (1LSM) therapy following chemotherapy (CT) plus bevacizumab (bev) induction treatment in patients (pts) with epithelial ovarian cancer (EOC) in the SW1TCH study.
Authors
BJ Rimel
Cedars-Sinai Medical Center, Los Angeles, CA
BJ Rimel, Tirza Areli Calderón Boyle, Jessica Perhanidis, Sara Burns, Jonathan Lim, John Hartman, Linda Kalilani, Jeanne M. Schilder, Jean A. Hurteau, Amanda Golembesky
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B
Track
Health Care Access, Equity, and Disparities,Technology and Innovation in Quality of Care,Palliative and Supportive Care
Sub Track
Real-World Evidence
Citation
JCO Oncol Pract 19, 2023 (suppl 11; abstr 536)
DOI
10.1200/OP.2023.19.11_suppl.536
Abstract #
536
Poster Bd #
L11
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
ENGOT-OV43/KEYLYNK-001: A phase III, randomized, double-blind, active- and placebo-controlled study of pembrolizumab plus chemotherapy with olaparib maintenance for first-line treatment of BRCA-nonmutated advanced epithelial ovarian cancer.
First Author: Ignace Vergote
Poster
2019 ASCO Annual Meeting
Recurrence of ovarian cancer in BRCAwt patients without maintenance therapy: Real-world evidence.
First Author: Melinda Louie-Gao
Poster
2023 ASCO Annual Meeting
Exploring the significance of PARP inhibitor therapy after first-line chemotherapy in patients with homologous recombination proficient ovarian cancer: An extracted individual patient data and trial-level meta-analysis.
First Author: Mateus Trinconi Cunha
Poster
2019 ASCO Annual Meeting
Real-world bevacizumab utilization and outcomes in first-line ovarian cancer.
First Author: Matthew J. Monberg